Derrame Pleural en Tuberculosis No Asociada A VIH

8/17/2015
Tuberculous pleural effusions in HIV-negative patients
Official reprint from UpToDate

www.uptodate.com 2015 UpToDate

Author
Michael D Frye, MD
Section Editor
C Fordham von Reyn, MD
Deputy Editor
Elinor L Baron, MD, DTMH
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jul 2015. | This topic last updated: Feb 19, 2015.
INTRODUCTION Tuberculous pleural effusion accounts for approximately 5 percent of disease due to Mycobacterium tuberculosis and is the second
most common form of extrapulmonary tuberculosis (TB) after lymphatic involvement [1,2].
Issues related to the diagnosis and treatment of tuberculous pleural effusions in HIV-negative patients will be reviewed here. Issues related to tuberculous
pleural effusions in HIV-infected patients are discussed separately. (See "Tuberculous pleural effusions in HIV-infected patients".)
PATHOGENESIS Tuberculous pleural effusions are thought to result from a delayed hypersensitivity reaction to mycobacteria and mycobacterial
antigens in the pleural space [3]. These organisms and/or their antigens probably enter the pleural space due to leakage or rupture of a subpleural focus of
disease. In one study of 24 patients with tuberculous pleural effusions who underwent thoracotomy, for example, a caseous focus in the lung contiguous
with the diseased pleura was found in half of cases [4]. Development of pleural effusion occurs largely as a result of hypersensitivity reaction, but
tuberculous pleurisy must be considered to be due to infection since culture of the fluid grows mycobacteria in some cases and culture of the pleural
tissue usually grows mycobacteria. Tuberculous pleural effusions are usually self-limited and resolve spontaneously with or without treatment in most
cases. However, the condition can potentially progress and worsen and become a tuberculous empyema.
A tuberculous empyema represents chronic active infection of the pleural space and can occur in the setting of a large pleural effusion that progresses,
usually leading to an unexpandable lung [5]. Simple tuberculous pleural effusion and tuberculous empyema can be considered a continuum of the same
process. Tuberculous empyema can also develop via extension of infection from thoracic lymph nodes or subdiaphragmatic focus, via hematogenous
spread, or in the setting of therapeutic pneumothorax therapy leading to an unexpandable lung.
In an experimental model of tuberculous effusion in which Bacille Calmette-Gurin (BCG) was injected into the pleural space of rabbits that had been
previously sensitized with intradermal BCG, a sequential influx of cells into the pleural space was observed [6]. An initial neutrophilic response is
necessary for the subsequent mononuclear influx [7]. Macrophages are the predominant mononuclear cells until day four, with lymphocytes predominating
thereafter [6]. The local release of cytokines probably induces the sequential expression of specific cell adhesion molecules in vascular endothelium that
direct the influx of the different inflammatory cells.
In patients with tuberculous pleural effusion, the proportion of T lymphocytes is higher in pleural fluid than in blood. This is due to selective enrichment of
cells with the helper/inducer (CD4) phenotype via local proliferation and probable selective influx. Those pleural helper T cells with a "memory" phenotype
(CD4+, CDw29+) are the cells that proliferate and produce gamma interferon when stimulated with purified protein derivative (PPD) [8].
CLINICAL MANIFESTATIONS Tuberculous pleural effusions can occur in association with either reactivation disease or primary tuberculosis (TB) [9http://www.uptodate.com.wdg.biblio.udg.mx:2048/contents/tuberculous-pleural-effusions-in-hiv-negative-patients?topicKey=ID%2F8012&elapsedTimeMs=0&source=search_result&searchTerm=extrapulmonary+tub
1/11
8/17/2015
12]. Most often they are due to reactivation disease in adults [10,11] and to primary disease in children [12]. Tuberculous pleural effusions are typically
unilateral and small to moderate in size [9].
Patients with tuberculous pleural effusion usually have acute febrile illness with nonproductive cough (94 percent) and pleuritic chest pain (78 percent),
without an elevation in the peripheral white blood cell count [13]. Night sweats, chills, weakness, dyspnea, and weight loss can also occur. The average
age in one series from the United States was 47 years [1].
In some cases, pleural scarring can lead to a "trapped lung" and pleural fluid fills the void created by the nonexpandable lung. Less commonly, tuberculous
pleural effusion can develop when a cavity ruptures into the pleural space, resulting in a chronic suppurative effusion, called a chronic tuberculous
empyema [5,14]. Chronic tuberculous empyema is characterized by purulent fluid containing numerous tuberculous organisms and results in thickened,
scarred, and calcified pleura.
Radiographic imaging Tuberculous pleural effusions are unilateral in almost all cases and occur slightly more frequently on the right side than the left
(55 versus 45 percent) [15,16]. The effusions are typically small to moderate in size; they occupy less than one-third of the hemithorax in 82 percent of
cases [15]. The size or side of the effusion has no bearing on prognosis [17].
Parenchymal disease has been observed in association with pleural effusion on chest radiography in up to 50 percent of patients [1]. These findings are
located in the upper lobe in approximately three-fourths of cases, suggestive of reactivation TB. In the remaining patients, parenchymal disease is located
in the lower lobe and resembles primary disease. The effusion virtually always occurs on the same side as the parenchymal infiltrate [13]. Computed
tomography (CT) is more sensitive than chest radiography; it demonstrates parenchymal disease in over 80 percent of cases, supporting the theory of
spread to the pleura from a subpleural focus of infection (image 1) [18]. In patients without apparent parenchymal involvement, pleural disease may develop
via hematogenous spread following primary infection.
DIAGNOSIS Diagnostic evaluation of pleural effusion in the setting of suspected tuberculosis (TB) begins with thoracentesis; fluid should be sent for
routine studies and additional assays as discussed below. In the setting of moderate to high suspicion for tuberculosis with nondiagnostic pleural fluid
evaluation, pleural biopsy is warranted.
In addition to pleural evaluation, routine laboratory diagnostic evaluation for TB should also be pursued; this is discussed in detail separately. Evaluation for
concurrent HIV infection should also be performed. (See "Diagnosis of pulmonary tuberculosis in HIV-uninfected patients" and "Epidemiology, clinical
manifestations, and diagnosis of tuberculosis in HIV-infected patients".)
Pleural fluid Evaluation of pleural fluid consists of routine studies, as outlined below. The additional assays described are not required for routine
evaluation but can be helpful in some cases if the diagnosis is difficult to establish based on routine pleural studies and pleural biopsy.
Routine studies The pleural fluid in tuberculous pleural effusion is straw colored in more than 80 percent of cases [19]. It is uniformly exudative [15];
the protein concentration is invariably >3.0 g/dL (30 g/L), and >5.0 g/dL (50 g/L) in 50 to 77 percent of cases [13,20]. The pleural fluid lactate
dehydrogenase (LDH) level is elevated in approximately 75 percent of cases, with levels commonly exceeding 500 IU/L [1,13,15,20].
Low pH and low glucose concentration may be observed; these findings are more characteristic of chronic tuberculous empyema than tuberculous pleural
effusion. The pleural fluid pH is virtually always <7.40; pH <7.30 is observed in about 20 percent of cases. The pleural fluid glucose concentration in
tuberculous pleural effusion is usually between 60 and 100 mg/dL (3.3 and 5.6 mmol/L). Glucose levels below 50 mg/dL (2.8 mmol/L) are observed in 7 to
http://www.uptodate.com.wdg.biblio.udg.mx:2048/contents/tuberculous-pleural-effusions-in-hiv-negative-patients?topicKey=ID%2F8012&elapsedTimeMs=0&source=search_result&searchTerm=extrapulmonary+tub
2/11
8/17/2015
20 percent of effusions. Extremely low glucose concentrations (<30 mg/dL [1.7 mmol/L]) can occur occasionally [13,20]. (See 'Pathogenesis' above.)
The pleural fluid nucleated cell count is usually between 1000 and 6000 cells/mm3 [15]. It is lymphocyte predominant in 60 to 90 percent of cases; the
remaining cases have neutrophil predominance [1,13,20]. Timing is important in the type of nucleated cells that are seen; neutrophils predominate in the
first few days of a tuberculous pleural effusion and lymphocytes predominate thereafter [6,7,19]. The pleural fluid rarely contains more than 5 percent
mesothelial cells. Eosinophil infiltration is uncommon. The presence of more than 10 percent eosinophils usually excludes the diagnosis of tuberculous
pleuritis unless the patient has had a pneumothorax or hemothorax near the time of pleural analysis [21]. (See "Pleural fluid eosinophilia".)
Pleural fluid cultures are positive in 12 to 80 percent of patients; most series note positive cultures in less than 20 to 30 percent of cases [9]. The addition
of pleural biopsy culture may increase the yield to >90 percent [9,19]. (See 'Pleural biopsy' below.)
Nucleic acid amplification techniques for evaluation of tuberculous pleural effusion in HIV-negative patients appear to have high specificity but relatively low
sensitivity [22,23]. In one systemic review and meta-analysis including 18 studies, the sensitivity and specificity for the Xpert MTB/RIF assay (compared
with culture) in pleural fluid were 46 and 99 percent, respectively [23]. (See "Diagnosis of pulmonary tuberculosis in HIV-uninfected patients", section on
'Nucleic acid amplification'.)
Additional assays Additional assays for evaluation of pleural fluid in the setting of suspected TB include measurement of pleural fluid adenosine
deaminase (ADA) level, lysozyme concentration, and interferon-gamma (IFN-gamma) concentration. Of these tests, the pleural fluid ADA level is most
clinically useful and accessible. An ADA level should be sent along with the routine pleural fluid studies whenever TB is the suspected cause of the
effusion. Even when the acid-fast bacilli (AFB) smear and culture are negative, compatible routine studies along with an elevated ADA level may establish
a presumptive diagnosis of tuberculous pleuritis in the right clinical setting.
ADA levels are most useful in patients with moderate to high suspicion for TB with negative pleural histology and culture [24]. Some large series suggest
that a value >45 to 60 U/L is 100 percent sensitive and up to 97 percent specific for tuberculous pleural effusion [15,24-27]. However, one report of 87
cases found levels >43 U/L in only 78 percent of cases [28]; other series have documented specificities of 85 to 89 percent [29,30]. Pleural effusions with
an ADA level <40 U/L are rarely caused by TB [31]. Specificity is diminished by elevated ADA levels that can occur in other conditions, including
rheumatoid effusion, empyema, mesothelioma, lung cancer, parapneumonic effusion, and hematologic malignancies. These findings in part reflect failure to
distinguish between the two principal isoenzymes, ADA-1 and ADA-2; most assays report the total level only. ADA-2 is increased in tuberculous effusions,
while ADA-1 is increased in empyemas [32].
Pleural fluid lysozyme concentrations are >15 mg/dL in over 80 percent of tuberculous pleural effusions [27,33]. The highest concentrations are found in
empyemas, which can be tuberculous or bacterial. Lysozyme concentrations can also be elevated in the setting of malignant effusions. The pleural fluid-toserum lysozyme ratio may be more useful than the absolute value. Excluding empyemas, a ratio above 1.2 has been reported to have 100 percent
sensitivity for tuberculous effusions and 95 percent specificity [33]. In a heterogeneous group of 276 effusions, however, a threshold ratio of 1.1 was
associated with a sensitivity of only 67 percent; the specificity was 90 percent [27].
Measurement of pleural fluid interferon-gamma concentration by commercially available enzyme-linked immunosorbent assay kits may be a useful
diagnostic tool [34,35]. In one study including 145 patients with tuberculous pleural effusion, an IFN-gamma concentration >140 pg/mL had sensitivity and
specificity of 94 percent and 92 percent, respectively [27]. Another study including 66 patients with exudative, lymphocytic pleural effusions with cut-off
value of 240 pg/mL noted sensitivity and specificity of 95 and 96 percent (figure 1) [36]. A meta-analysis including 22 studies to estimate the accuracy of
interferon-gamma in the diagnosis of tuberculous pleural effusion were 89 and 97 percent, respectively [37]; other series have described lower sensitivity
3/11
8/17/2015
[30].
Pleural fluid tuberculous antigens and antituberculous antibodies have also been studied and appear to be elevated in tuberculous pleuritis. However, these
immunologic tests are not useful diagnostically due to lack of specificity for TB.
Pleural biopsy Pleural biopsy is warranted in the setting of moderate to high suspicion for TB when pleural fluid evaluation is not diagnostic. A
definitive diagnosis should be pursued in most cases when tuberculous pleurisy is suspected. Pleural biopsy offers the highest likelihood of a certain
diagnosis, and a positive culture also provides information pertaining to drug sensitivities of the organism. Pleural biopsy for confirmation of the diagnosis
may also be necessary when use of antituberculous medications poses a particularly high risk of complications, such as in patients with preexisting liver
disease.
Histologic examination and culture of pleural tissue is the most sensitive evaluation for pleural TB; this approach yields a diagnosis in 60 to 95 percent of
cases [9,19,38,39]. Pleural biopsy demonstrates granulomas in 50 to 97 percent of cases and culture of biopsy material is positive in 40 to 80 percent of
cases [9]. Sensitivity generally increases with the number of biopsies taken.
The presence of pleural caseating granulomas on histologic examination is virtually diagnostic of TB pleural effusion. Caseation and demonstration of acidfast bacilli are not required. Noncaseating pleural granulomas can occasionally be seen in other disorders, such as sarcoidosis, fungal disease, and
rheumatoid pleuritis.
Pleural tissue can be obtained via thoracoscopy or closed percutaneous needle biopsy. Sensitivities are comparable; needle biopsy is generally preferred
in areas where tuberculous pleuritis is common [40,41].
Other evaluation In addition to pleural evaluation, routine laboratory diagnostic evaluation for TB should also be pursued; this is discussed in detail
separately. Evaluation for concurrent HIV infection should also be performed. (See "Diagnosis of pulmonary tuberculosis in HIV-uninfected patients" and
"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients".)
Sputum culture is positive in 20 to 50 percent of patients with pleural effusion; positive sputum culture is more likely in the setting of concomitant
parenchymal disease [1,4,13,20,42]. In one report of 70 patients with tuberculous pleural effusions, sputum culture was positive in 89 percent of patients
with parenchymal changes but only 11 percent of patients without parenchymal changes [42]. The yields for induced sputum and pleural biopsy were 52
and 62 percent, respectively [42].
Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) can be useful components of the evaluation of suspected tuberculous pleural
effusions, although neither can distinguish between latent tuberculosis infection and active tuberculosis disease. Older series reported almost uniformly
positive TST results in patients with tuberculous pleural effusions; subsequent reports have observed false-negative tests in 7 to 30 percent of patients
[1,13]. Almost all patients with tuberculous pleural effusion and an initially negative TST have a positive TST if retested two months later. One possible
explanation for the initial negative TST is suppression of sensitized T cells in the peripheral circulation and skin by circulating adherent mononuclear cells
(chiefly monocytes, not classic CD8 suppressor cells). These monocytes are known to suppress antigen-induced lymphocyte blastogenesis and the
production of interleukin-2.
Interferon-gamma release assays can be used in place of TST and are discussed further separately. The use of IGRAs on pleural fluid for the diagnosis of
tuberculous pleuritis has been investigated and thus far appears to lack sufficient sensitivity and specificity for clinical use. A meta-analysis reported that
4/11
8/17/2015
IGRAs used on pleural fluid in patients with tuberculous pleuritis has a sensitivity and specificity of 75 and 82 percent, respectively [43]. (See "Interferongamma release assays for diagnosis of latent tuberculosis infection".)
MANAGEMENT AND OUTCOME Treatment of tuberculous pleural effusion is similar to treatment of pulmonary tuberculosis (TB). This is discussed in
detail separately. (See "Treatment of pulmonary tuberculosis in HIV-uninfected patients" and "Treatment of pulmonary tuberculosis in the HIV-infected
patient".)
In some cases, the diagnosis rests on clinical rather than microbiologic or histologic criteria. Presumptive therapy is warranted for patients with
lymphocytic exudate and a positive tuberculin skin test or interferon-gamma release assay, even in the absence of definitive diagnosis [44]. In the absence
of treatment for tuberculous pleuritis, patients have a 65 percent risk of developing pulmonary or extrapulmonary TB within five years [45]. (See "Diagnosis
of pulmonary tuberculosis in HIV-uninfected patients" and "Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients".)
Routine complete drainage of pleural fluid at the time of diagnosis does not appear to improve long-term outcomes. This was demonstrated in a
randomized trial including 61 patients with newly diagnosed tuberculous pleural effusion treated with anti-TB therapy with or without pigtail drainage [46].
Drainage was associated with significantly more rapid resolution of dyspnea (four versus eight days), although after the first week there were no differences
in symptoms between groups during the 24-week follow-up period. Pulmonary function and the degree of residual pleural thickening on chest radiography
were the same in both groups at the conclusion of the trial.
With appropriate therapy, most patients defervesce within two weeks; in most cases, pleural fluid is resorbed within six weeks. However, some patients
take up to two months to defervesce, and fluid resorption may take up to four months. In selected patients, administration of corticosteroids can shorten
the duration of fever and time to fluid resorption, although the precise risks and benefits of corticosteroids in this setting have not been well defined [47,48].
Data are insufficient to support routine adjunctive use of corticosteroids for tuberculous pleuritis [49,50].
Residual pleural thickening can occur in 50 percent of patients [51]. Among 56 patients with 10 mm of residual pleural thickening following completion of
medical therapy, the pleural fluid had a significantly lower pH, lower glucose concentration, higher lysozyme concentration, and higher tumor necrosis
factor-alpha levels; the adenosine deaminase level was elevated to a similar degree in both groups [52].
SUMMARY
Tuberculous pleural effusions can occur in association with either primary tuberculosis (TB) or reactivation disease. Patients with tuberculous pleural
effusion usually have acute febrile illness with nonproductive cough and pleuritic chest pain. Night sweats, chills, weakness, dyspnea, and weight
loss can also occur. (See 'Clinical manifestations' above.)
Tuberculous pleural effusions are usually small to moderate in size, unilateral, and occur slightly more frequently on the right side than the left.
Parenchymal disease may be observed in association with pleural effusion. Most often, parenchymal disease is in the upper lobe, suggestive of
reactivation TB; in some cases, parenchymal disease is in the lower lobe and resembles primary disease. (See 'Radiographic imaging' above.)
Diagnostic evaluation of pleural effusion in the setting of suspected tuberculous pleuritis begins with thoracentesis. The pleural fluid is generally
exudative with protein concentration >3.0 g/dL and lactate dehydrogenase level commonly exceeding 500 IU/L. Low pH and low glucose
concentration may be observed; these findings are more characteristic of chronic tuberculous empyema than tuberculous pleural effusion. The pleural
fluid nucleated cell count is usually lymphocyte predominant. Cultures are positive in <30 percent of cases. (See 'Routine studies' above.)
5/11
8/17/2015
Pleural biopsy is warranted in the setting of moderate to high suspicion for TB when pleural fluid evaluation is suggestive of TB pleuritis but not
diagnostic. Histologic examination and culture of pleural tissue is the most sensitive evaluation for pleural TB. The presence of pleural caseating
granulomas on histologic examination is virtually diagnostic of TB pleural effusion. (See 'Pleural biopsy' above.)
Additional assays for evaluation of pleural fluid in the setting of suspected TB (such as pleural fluid adenosine deaminase level, lysozyme
concentration, and interferon-gamma concentration) can be helpful to establish a presumptive diagnosis of tuberculous pleuritis. The pleural fluid
adenosine deaminase level is the most clinically useful of these assays. However, a definitive diagnosis made with acid-fast bacilli (AFB) smear,
culture, and sensitivities should be pursued whenever possible. (See 'Additional assays' above.)
In addition to pleural evaluation, routine laboratory diagnostic evaluation for TB should also be pursued; this is discussed in detail separately.
Evaluation for concurrent HIV infection should also be performed. (See "Diagnosis of pulmonary tuberculosis in HIV-uninfected patients" and
"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients".)
Treatment of tuberculous pleural effusion is similar to treatment of pulmonary TB. Presumptive therapy is warranted for patients with lymphocytic
exudate and a positive tuberculin skin test or serum interferon-gamma release assay, even in the absence of definitive diagnosis. With appropriate
therapy, most patients defervesce within two weeks; in most cases, pleural fluid is resorbed within six weeks. Residual pleural thickening can occur.
(See 'Management and outcome' above.)
ACKNOWLEDGMENT The editorial staff at UpToDate, Inc. would like to acknowledge Steven Sahn, MD, who contributed to an earlier version of this
topic review.
Use of UpToDate is subject to the Subscription and License Agreement.
REFERENCES
1. Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion. Twenty-year experience. Chest 1991; 99:883.
2. Baumann MH, Nolan R, Petrini M, et al. Pleural tuberculosis in the United States: incidence and drug resistance. Chest 2007; 131:1125.
3. Leibowitz S, Kennedy L, Lessof MH. The tuberculin reaction in the pleural cavity and its suppression by antilymphocyte serum. Br J Exp Pathol
1973; 54:152.
4. STEAD WW, EICHENHOLZ A, STAUSS HK. Operative and pathologic findings in twenty-four patients with syndrome of idiopathic pleurisy with
effusion, presumably tuberculous. Am Rev Tuberc 1955; 71:473.
5. Sahn SA, Iseman MD. Tuberculous empyema. Semin Respir Infect 1999; 14:82.
6. Antony VB, Repine JE, Harada RN, et al. Inflammatory responses in experimental tuberculosis pleurisy. Acta Cytol 1983; 27:355.
7. Antony VB, Sahn SA, Antony AC, Repine JE. Bacillus Calmette-Gurin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural
spaces and in vitro. J Clin Invest 1985; 76:1514.
8. Ellner JJ, Barnes PF, Wallis RS, Modlin RL. The immunology of tuberculous pleurisy. Semin Respir Infect 1988; 3:335.
9. Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 2007; 131:880.
6/11
8/17/2015
10. Torgersen J, Dorman SE, Baruch N, et al. Molecular epidemiology of pleural and other extrapulmonary tuberculosis: a Maryland state review. Clin
Infect Dis 2006; 42:1375.
11. Kim HJ, Lee HJ, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest 2006;
129:1253.
12. Merino JM, Carpintero I, Alvarez T, et al. Tuberculous pleural effusion in children. Chest 1999; 115:26.
13. Berger HW, Mejia E. Tuberculous pleurisy. Chest 1973; 63:88.
14. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the
Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of
the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.
15. Valds L, Alvarez D, San Jos E, et al. Tuberculous pleurisy: a study of 254 patients. Arch Intern Med 1998; 158:2017.
16. Frye MD, Pozsik CJ, Sahn SA. Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. Chest 1997; 112:393.
17. SIBLEY JC. A study of 200 cases of tuberculous pleurisy with effusion. Am Rev Tuberc 1950; 62:314.
18. Hulnick DH, Naidich DP, McCauley DI. Pleural tuberculosis evaluated by computed tomography. Radiology 1983; 149:759.
19. Levine H, Metzger W, Lacera D, Kay L. Diagnosis of tuberculous pleurisy by culture of pleural biopsy specimen. Arch Intern Med 1970; 126:269.
20. Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. Chest 1987; 91:106.
21. Light RW. Chapter 10. In: Pleural Diseases, 2d ed, Lea & Febiger, Philadelphia 1990.
22. Trajman A, da Silva Santos Kleiz de Oliveira EF, Bastos ML, et al. Accuracy of polimerase chain reaction for the diagnosis of pleural tuberculosis.
Respir Med 2014; 108:918.
23. Denkinger CM, Schumacher SG, Boehme CC, et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and
meta-analysis. Eur Respir J 2014; 44:435.
24. Piras MA, Gakis C, Budroni M, Andreoni G. Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis. Br Med J 1978;
2:1751.
25. Riantawan P, Chaowalit P, Wongsangiem M, Rojanaraweewong P. Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis
with reference to HIV coinfection and a Bayesian analysis. Chest 1999; 116:97.
26. Ocaa I, Martinez-Vazquez JM, Segura RM, et al. Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest
1983; 84:51.
27. Valds L, San Jos E, Alvarez D, et al. Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and
interferon gamma. Chest 1993; 103:458.
28. Orriols R, Coloma R, Ferrer J, et al. Adenosine deaminase in tuberculous pleural effusion. Chest 1994; 106:1633.
29. Baales JL, Pineda PR, Fitzgerald JM, et al. Adenosine deaminase in the diagnosis of tuberculous pleural effusions. A report of 218 patients and
review of the literature. Chest 1991; 99:355.
30. Villegas MV, Labrada LA, Saravia NG. Evaluation of polymerase chain reaction, adenosine deaminase, and interferon-gamma in pleural fluid for the
differential diagnosis of pleural tuberculosis. Chest 2000; 118:1355.
31. Jimnez Castro D, Daz Nuevo G, Prez-Rodrguez E, Light RW. Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural
7/11
8/17/2015
effusions. Eur Respir J 2003; 21:220.

32. Gakis C. Adenosine deaminase in pleural effusions. Chest 1995; 107:1772.
33. Verea Hernando HR, Masa Jimenez JF, Dominguez Juncal L, et al. Meaning and diagnostic value of determining the lysozyme level of pleural fluid.
Chest 1987; 91:342.
34. Hiraki A, Aoe K, Eda R, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest 2004; 125:987.
35. Aoe K, Hiraki A, Murakami T, et al. Diagnostic significance of interferon-gamma in tuberculous pleural effusions. Chest 2003; 123:740.
36. Wongtim S, Silachamroon U, Ruxrungtham K, et al. Interferon gamma for diagnosing tuberculous pleural effusions. Thorax 1999; 54:921.
37. Jiang J, Shi HZ, Liang QL, et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest 2007; 131:1133.
38. Kirsch CM, Kroe DM, Azzi RL, et al. The optimal number of pleural biopsy specimens for a diagnosis of tuberculous pleurisy. Chest 1997; 112:702.
39. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988; 138:184.
40. Diacon AH, Van de Wal BW, Wyser C, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J 2003; 22:589.
41. Emad A, Rezaian GR. Diagnostic value of closed percutaneous pleural biopsy vs pleuroscopy in suspected malignant pleural effusion or tuberculous
pleurisy in a region with a high incidence of tuberculosis: a comparative, age-dependent study. Respir Med 1998; 92:488.
42. Conde MB, Loivos AC, Rezende VM, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med 2003;
167:723.
43. Zhou Q, Chen YQ, Qin SM, et al. Diagnostic accuracy of T-cell interferon- release assays in tuberculous pleurisy: a meta-analysis. Respirology
2011; 16:473.
44. Losi M, Bossink A, Codecasa L, et al. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J 2007;
30:1173.
45. ROPER WH, WARING JJ. Primary serofibrinous pleural effusion in military personnel. Am Rev Tuberc 1955; 71:616.
46. Lai YF, Chao TY, Wang YH, Lin AS. Pigtail drainage in the treatment of tuberculous pleural effusions: a randomised study. Thorax 2003; 58:149.
47. Lee CH, Wang WJ, Lan RS, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study.
Chest 1988; 94:1256.
48. Matchaba PT, Volmink J. Steroids for treating tuberculous pleurisy. Cochrane Database Syst Rev 2000; :CD001876.
49. Light RW. Update on tuberculous pleural effusion. Respirology 2010; 15:451.
50. Engel ME, Matchaba PT, Volmink J. Corticosteroids for tuberculous pleurisy. Cochrane Database Syst Rev 2007; :CD001876.
51. Barbas CS, Cukier A, de Varvalho CR, et al. The relationship between pleural fluid findings and the development of pleural thickening in patients with
pleural tuberculosis. Chest 1991; 100:1264.
52. de Pablo A, Villena V, Echave-Sustaeta J, Encuentra AL. Are pleural fluid parameters related to the development of residual pleural thickening in
tuberculosis? Chest 1997; 112:1293.
Topic 8012 Version 11.0
8/11
8/17/2015
GRAPHICS
Tuberculous pleural effusion
Computed tomography (CT) sc an showing a parenc hymal foc us of

tuberc ulosis c lose to the pleura and an ipsilateral pleural effusion.
Courtesy of Paul Stark, MD.
Graphic 63772 Version 3.0
9/11
8/17/2015
Interferon-gamma in tuberculous pleural effusions
One study in 66 patients with exudative, lymphoc ytic pleural effusions found a
sensitivity of 95 perc ent and a spec ific ity of 96 perc ent for pleural fluid
interferon-gamma c onc entrations when a c ut-off value of 240 pg/mL was
employed.
Data from Wongtim S, Silachamroon U, Ruxrungtham K, et al. Thorax 1999; 54:921.
Graphic 72138 Version 2.0
http://www.uptodate.com.wdg.biblio.udg.mx:2048/contents/tuberculous-pleural-effusions-in-hiv-negative-patients?topicKey=ID%2F8012&elapsedTimeMs=0&source=search_result&searchTerm=extrapulmonary+tu
10/11
8/17/2015
Disclosures
Disclosures: Michael D Frye, MD Nothing to disclose. C Fordham von Reyn, MD Nothing to disclose. Elinor L Baron, MD, DTMH Nothing
to disclose.
Contributor disclosures are review ed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a
multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is
required of all authors and must conform to UpToDate standards of evidence.
Conflict of interest policy
http://www.uptodate.com.wdg.biblio.udg.mx:2048/contents/tuberculous-pleural-effusions-in-hiv-negative-patients?topicKey=ID%2F8012&elapsedTimeMs=0&source=search_result&searchTerm=extrapulmonary+tu
11/11

Derrame Pleural en Tuberculosis No Asociada A VIH

Cargado por

Información del documento

Título original

Derechos de autor

Formatos disponibles

Compartir este documento

Compartir o incrustar documentos

Opciones para compartir

¿Le pareció útil este documento?

¿Este contenido es inapropiado?

Copyright:

Formatos disponibles

Derrame Pleural en Tuberculosis No Asociada A VIH

Cargado por

Copyright:

Formatos disponibles

8/17/2015

Tuberculous pleural effusions in HIV-negative patients

Official reprint from UpToDate

Tuberculous pleural effusions in HIV-negative patients

Tuberculous pleural effusions in HIV-negative patients

Tuberculous pleural effusions in HIV-negative patients

Tuberculous pleural effusions in HIV-negative patients

Tuberculous pleural effusions in HIV-negative patients

Tuberculous pleural effusions in HIV-negative patients

Tuberculous pleural effusions in HIV-negative patients

Tuberculous pleural effusions in HIV-negative patients

effusions. Eur Respir J 2003; 21:220.

Tuberculous pleural effusions in HIV-negative patients

Computed tomography (CT) sc an showing a parenc hymal foc us of

Tuberculous pleural effusions in HIV-negative patients

Interferon-gamma in tuberculous pleural effusions

Tuberculous pleural effusions in HIV-negative patients

También podría gustarte